MY Mom has been legally blind for years, she has glaucoma. One of her eyes is dead, she sees nothing with it. Over this past year she has lost most of her sight in her other eye, now she can only see shapes and variations of light. We thank God for the treatment and care she has received since MAY this year from Dr Sabita Ittoop, if it wasn't for her aggressive treatment of and actual concern for my Mom she would be totally blind by now. I strongly recommend anyone with glaucoma to consider contacting Dr Ittoop at Glaucoma Consultants of Washington
if you are going blind from glaucoma and / or are not satisfied with the care and treatment you are receiving.
These articles from +NPR give me hope for my Mom, I got goosebumps when I heard the first one while getting ready for work. They also make me a bit angry because if a minority of radical religious fanatics had not stopped funding for research using embryonic stem cells maybe my Mom would not be as blind as she is, maybe she would have sight in both her eyes. My siblings and I will be checking this out as a possible treatment for our Mom as she has said she is willing to participate in clinical trials.
Scientists are reporting the first strong evidence that human embryonic stem cells may be helping patients.
The cells appear to have improved the vision in more than half of the 18 patients who had become legally blind because of two progressive, currently incurable eye diseases.
The researchers stress that the findings must be considered preliminary because the number of patients treated was relatively small and they have only been followed for an average of less than two years.
But the findings are quite promising. The patients had lost so much vision that there was no expectation that they could benefit, the researchers say.
"I'm astonished that this is working in the way that it is — or seems to be working," says Steven Schwartz, a UCLA eye specialist who led the study, which was published Tuesday in the British medical journal The Lancet. "I'm very excited about it."
Other researchers agreed the work is preliminary, but also highly promising.
"It really does show for the very first time that patients can, in fact, benefit from the therapy," says Dr. Anthony Atala, a surgeon and director of the Wake Forest Institute for Regenerative Medicine at Wake Forest University.
"That allows you to say, 'OK, now that these cells have been used
for patients who have blindness, maybe we can also use these cells for
many other conditions as well, including heart disease, lung disease and
other medical conditions,' " Atala says.
Human embryonic stem cells have the ability to become any kind of cell in the body. So scientists have been hoping the cells could be used to treat many diseases, including Alzheimer's, diabetes and paralysis. But the study is the first human embryonic stem cell trial approved by the Food and Drug Administration that has produced any results.
"It is really a very important paper," Atala says.
The study involved patients suffering from age-related macular degeneration and Stargardt's macular dystrophy, the two leading causes of adult and juvenile blindness in the developed world, Schwartz says. The diseases destroy a person's central vision.
"Whatever you're looking at is gone — whether it's faces, or reading or food on a plate, or whether something is a step or stripe," Schwartz says. "It's very, very difficult to perform activities of daily life that we, you know, don't even think about."
Working with Advanced Cell Technology Inc. of Marlborough, Mass., Schwartz and his colleagues took human embryonic stem cells and turned them into the kind of cells that are killed by these diseases — retinal pigment epithelial cells. Then, they infused between 50,000 and 150,000 cells into the retinas of the patients.
"What we did is put them into patients who have a disease where those particular cells are dying; and we replaced those dying tissues with new tissue that's derived from these stem cells," Schwartz said. "In a way it's a retinal transplant."
No one expected the cells to help any of these patients see
better, because the study was designed mostly just to see if doing this
was safe. Researchers were concerned the cells could destroy whatever
vision was left or lead to tumors in the volunteers' eyes. So Schwartz
picked patients whose eyes were so far gone that they weren't risking
losing any vision. That also meant that there was little hope the cells
could help either.
"We did not expect to help these patients, and they did not expect to be helped," Schwartz says.
Some patients experienced side effects from the procedure itself and from the drugs they had to take to suppress the immune system, but none of the side effects were considered serious. The cells themselves have produced no safety problems so far, the researchers reported.
And, surprisingly, many of the patients did start to see better, according to the report. Ten of the 18 patients can see significantly better. One got worse, but the other seven either got better or didn't lose any more vision.
"These are patients that didn't see better for 30 years and all of a sudden they're seeing better," Schwartz says. "It's amazing."
The patients include a graphic artist who could suddenly make out the woodwork carved on a piece of furniture in her bedroom, an international consultant who regained the ability to walk through busy airports without help, and an elderly rancher who's riding his horse again, Schwartz says.
"He couldn't see things like a barbed-wire fence or whether in the distance a stray cow was under a tree," Schwartz says. "And six months after the transplant he's back to running his cattle again. And he can, in fact, see a snake on the ground or sort of tell whether a distant shadow is a cow or something else. So it's made a big difference for him in his life."
Isabella Beukes of Santa Rosa, Calif., has been legally blind for more than 40 years. But within weeks of getting the cells, she started to see better. She could make out the cursor on her computer screen and the color of her clothes. Today, she can hike the hills near her house all by herself.
"The improvement, I mean, from where I was coming is just, it's very, very significant for me. I think it's fantastic," Beukes says. "I just think to be part of groundbreaking research work is amazing."
The research is controversial, however. Embryos are destroyed to get the cells, and some people think that's immoral.
"The problem we have with embryonic stem cells is simply the fact that you have to destroy a young human being to get embryonic stem cells," says David Prentice, senior fellow for life science at the Family Research Council, an advocacy group. "We would reject the idea that any human being be destroyed for experimental purposes."
For his part, Schwartz says he's just trying to help blind people see better. But he cautions that this work is still at a very early stage.
"I don't want patients to come in to their doctor saying, 'Hey, I heard about the stem cells on the radio and I'd really like to get that treatment done, and what do you think?' " he says. "It's not ready. Maybe in a few years. Maybe not. We have to wait and see. The jury is way out still."
Schwartz has continued treating more patients using larger doses of cells and trying it on patients who haven't lost as much vision to see if that works even better. He has also expanded his study to Boston, Miami, Philadelphia and London.
For the first time, scientists are reporting that human embryonic
stem cells may be helping treat patients — in one instance, the cells
seem to been enabling some blind people to see better.
For the first time ever, scientists are reporting that human embryonic stem cells may be helping treat patients. In the medical journal The Lancet, researchers describe how the cells seem to help restore eyesight to some blind people.
NPR's Rob Stein has the details of the first study to demonstrate that embryonic stem cells could alleviate human suffering.
ROB STEIN, BYLINE: Human embryonic stem cells can be turned into any kind of cell in the body. So scientists have been hoping they could treat lots of diseases. But no one's done a careful study to find out if that's true until now. Steven Schwartz at UCLA tried using stem cells to help people suffering from two types of incurable eye diseases.
STEVEN SCHWARTZ: These represent the two leading causes of adult and juvenile blindness in the developed world.
STEIN: They're called age-related macular degeneration and Stargardt's macular dystrophy. They don't make people totally blind, but they destroy everything but peripheral vision.
SCHWARTZ: Whatever you're looking at is gone whether it's faces or reading or food on a plate or whether something's a step or a stripe. It's very, very difficult to perform activities of daily life that we, you know, don't even think about.
STEIN: Here's what they did. Schwartz and his colleagues took human embryonic stem cells and turned them into the kinds of cells that are killed by these diseases. Then, they infused tens of thousands of these cells into the retinas of 18 patients.
SCHWARTZ: What we did is put them into patients who have a disease where those particular cells are dying. And we replaced those dying tissues with new tissue that's derived from these stem cells. In a way, it's a retinal transplant.
STEIN: The study was designed mostly just to see if doing this was safe. There were big worries the whole thing could backfire. The cells could destroy whatever vision was left or turn into horrible tumors in the volunteer's eyes. So Schwartz picked patients whose eyes were so far gone that they weren't risking losing any vision. But that meant there was little hope the cells could help patients either.
SCHWARTZ: We did not expect to help these patient. And they did not expect to be helped.
STEIN: It's been nearly two years since the first patients got the cells. And so far, there are no signs of any safety problems. And to everyone's surprise, a lot of the patients did start to see better. Ten of the 18 patients can see a lot better. One got worse, but the other seven either got better or didn't lose any more vision.
SCHWARTZ: These are patients that didn't see better for 30 years, and all of a sudden, they're seeing better. It's amazing.
STEIN: There's a graphic artist who could suddenly make out the woodwork carved on a piece of furniture in her bedroom, an international consultant who eventually regained the ability to walk through busy airports without help, and an elderly rancher who's riding his horse again.
SCHWARTZ: He couldn't see things like barbed wire fence or whether in the distance a stray cow was under tree. And six months after the transplant, he's back to running his cattle again. And he can, in fact, see a snake on the ground or see a barbed wire fence from his horse or tell whether or not a distant shadow is a cow or something else. And so it's made a huge difference for him in his life.
STEIN: Isabella Bewkes (ph) of Santa Rosa, California has been legally blind for more than 40 years. But within weeks of getting the cells, she started to see better. She could make out the cursor on her computer screen, the color of her clothes. Today, she can hike the hills near her house all by herself.
ISABELLA BEWKES: The improvement, I mean from where I was coming, is just - it's very, very significant for me. I think it's fantastic. I just think to be part of groundbreaking research work is amazing.
STEIN: This research is controversial. Embryos are destroyed to get the cells. Some people think that's immoral. For his part, Schwartz says he's just trying to help blind people see better. But he cautions that this work is still at a very early stage. He's only treated a few dozen patients altogether so far and followed them for just 22 months.
SCHWARTZ: I don't want to increase suffering by creating expectations that can't be met.
STEIN: Other researchers agree that these findings need to be considered preliminary, but they say the results so far are really promising. Anthony Atala is at Wake Forest University.
ANTHONY ATALA: It's really a very important paper because it really does show for the very first time that patients can in fact benefit from the therapy that allows you to say OK, now these cells have been used for patients who have blindness. Maybe we can also use these cells for many other conditions as well, including heart disease and lung disease and other medical conditions.
STEIN: Schwartz has continued treating more blind patients using bigger doses of cells and trying it on patients who haven't lost as much vision to see if that works even better. He's also expanded his study to Boston, Miami, Philadelphia and London. Rob Stein, NPR News.
if you are going blind from glaucoma and / or are not satisfied with the care and treatment you are receiving.
These articles from +NPR give me hope for my Mom, I got goosebumps when I heard the first one while getting ready for work. They also make me a bit angry because if a minority of radical religious fanatics had not stopped funding for research using embryonic stem cells maybe my Mom would not be as blind as she is, maybe she would have sight in both her eyes. My siblings and I will be checking this out as a possible treatment for our Mom as she has said she is willing to participate in clinical trials.
Isabella Beukes, of Santa Rosa, Calif., has been legally
blind for more than 40 years. An experimental treatment derived from
embryonic stem cells seems to have enabled her now to see not just color
but also some shapes.
Tim Hussin for NPR
The cells appear to have improved the vision in more than half of the 18 patients who had become legally blind because of two progressive, currently incurable eye diseases.
The researchers stress that the findings must be considered preliminary because the number of patients treated was relatively small and they have only been followed for an average of less than two years.
But the findings are quite promising. The patients had lost so much vision that there was no expectation that they could benefit, the researchers say.
"I'm astonished that this is working in the way that it is — or seems to be working," says Steven Schwartz, a UCLA eye specialist who led the study, which was published Tuesday in the British medical journal The Lancet. "I'm very excited about it."
Other researchers agreed the work is preliminary, but also highly promising.
"It really does show for the very first time that patients can, in fact, benefit from the therapy," says Dr. Anthony Atala, a surgeon and director of the Wake Forest Institute for Regenerative Medicine at Wake Forest University.
Human embryonic stem cells have the ability to become any kind of cell in the body. So scientists have been hoping the cells could be used to treat many diseases, including Alzheimer's, diabetes and paralysis. But the study is the first human embryonic stem cell trial approved by the Food and Drug Administration that has produced any results.
"It is really a very important paper," Atala says.
The study involved patients suffering from age-related macular degeneration and Stargardt's macular dystrophy, the two leading causes of adult and juvenile blindness in the developed world, Schwartz says. The diseases destroy a person's central vision.
"Whatever you're looking at is gone — whether it's faces, or reading or food on a plate, or whether something is a step or stripe," Schwartz says. "It's very, very difficult to perform activities of daily life that we, you know, don't even think about."
Working with Advanced Cell Technology Inc. of Marlborough, Mass., Schwartz and his colleagues took human embryonic stem cells and turned them into the kind of cells that are killed by these diseases — retinal pigment epithelial cells. Then, they infused between 50,000 and 150,000 cells into the retinas of the patients.
"What we did is put them into patients who have a disease where those particular cells are dying; and we replaced those dying tissues with new tissue that's derived from these stem cells," Schwartz said. "In a way it's a retinal transplant."
"We did not expect to help these patients, and they did not expect to be helped," Schwartz says.
Some patients experienced side effects from the procedure itself and from the drugs they had to take to suppress the immune system, but none of the side effects were considered serious. The cells themselves have produced no safety problems so far, the researchers reported.
And, surprisingly, many of the patients did start to see better, according to the report. Ten of the 18 patients can see significantly better. One got worse, but the other seven either got better or didn't lose any more vision.
"These are patients that didn't see better for 30 years and all of a sudden they're seeing better," Schwartz says. "It's amazing."
The patients include a graphic artist who could suddenly make out the woodwork carved on a piece of furniture in her bedroom, an international consultant who regained the ability to walk through busy airports without help, and an elderly rancher who's riding his horse again, Schwartz says.
"He couldn't see things like a barbed-wire fence or whether in the distance a stray cow was under a tree," Schwartz says. "And six months after the transplant he's back to running his cattle again. And he can, in fact, see a snake on the ground or sort of tell whether a distant shadow is a cow or something else. So it's made a big difference for him in his life."
Isabella Beukes of Santa Rosa, Calif., has been legally blind for more than 40 years. But within weeks of getting the cells, she started to see better. She could make out the cursor on her computer screen and the color of her clothes. Today, she can hike the hills near her house all by herself.
"The improvement, I mean, from where I was coming is just, it's very, very significant for me. I think it's fantastic," Beukes says. "I just think to be part of groundbreaking research work is amazing."
Just being able to see well enough to to hike the hills
around her Santa Rosa home by herself is a huge improvement, Beukes
says.
Tim Hussin for NPR
"The problem we have with embryonic stem cells is simply the fact that you have to destroy a young human being to get embryonic stem cells," says David Prentice, senior fellow for life science at the Family Research Council, an advocacy group. "We would reject the idea that any human being be destroyed for experimental purposes."
For his part, Schwartz says he's just trying to help blind people see better. But he cautions that this work is still at a very early stage.
"I don't want patients to come in to their doctor saying, 'Hey, I heard about the stem cells on the radio and I'd really like to get that treatment done, and what do you think?' " he says. "It's not ready. Maybe in a few years. Maybe not. We have to wait and see. The jury is way out still."
Schwartz has continued treating more patients using larger doses of cells and trying it on patients who haven't lost as much vision to see if that works even better. He has also expanded his study to Boston, Miami, Philadelphia and London.
Copyright © 2014 NPR. For personal, noncommercial use only. See Terms of Use. For other uses, prior permission required.
AUDIE CORNISH, HOST: For the first time ever, scientists are reporting that human embryonic stem cells may be helping treat patients. In the medical journal The Lancet, researchers describe how the cells seem to help restore eyesight to some blind people.
NPR's Rob Stein has the details of the first study to demonstrate that embryonic stem cells could alleviate human suffering.
ROB STEIN, BYLINE: Human embryonic stem cells can be turned into any kind of cell in the body. So scientists have been hoping they could treat lots of diseases. But no one's done a careful study to find out if that's true until now. Steven Schwartz at UCLA tried using stem cells to help people suffering from two types of incurable eye diseases.
STEVEN SCHWARTZ: These represent the two leading causes of adult and juvenile blindness in the developed world.
STEIN: They're called age-related macular degeneration and Stargardt's macular dystrophy. They don't make people totally blind, but they destroy everything but peripheral vision.
SCHWARTZ: Whatever you're looking at is gone whether it's faces or reading or food on a plate or whether something's a step or a stripe. It's very, very difficult to perform activities of daily life that we, you know, don't even think about.
STEIN: Here's what they did. Schwartz and his colleagues took human embryonic stem cells and turned them into the kinds of cells that are killed by these diseases. Then, they infused tens of thousands of these cells into the retinas of 18 patients.
SCHWARTZ: What we did is put them into patients who have a disease where those particular cells are dying. And we replaced those dying tissues with new tissue that's derived from these stem cells. In a way, it's a retinal transplant.
STEIN: The study was designed mostly just to see if doing this was safe. There were big worries the whole thing could backfire. The cells could destroy whatever vision was left or turn into horrible tumors in the volunteer's eyes. So Schwartz picked patients whose eyes were so far gone that they weren't risking losing any vision. But that meant there was little hope the cells could help patients either.
SCHWARTZ: We did not expect to help these patient. And they did not expect to be helped.
STEIN: It's been nearly two years since the first patients got the cells. And so far, there are no signs of any safety problems. And to everyone's surprise, a lot of the patients did start to see better. Ten of the 18 patients can see a lot better. One got worse, but the other seven either got better or didn't lose any more vision.
SCHWARTZ: These are patients that didn't see better for 30 years, and all of a sudden, they're seeing better. It's amazing.
STEIN: There's a graphic artist who could suddenly make out the woodwork carved on a piece of furniture in her bedroom, an international consultant who eventually regained the ability to walk through busy airports without help, and an elderly rancher who's riding his horse again.
SCHWARTZ: He couldn't see things like barbed wire fence or whether in the distance a stray cow was under tree. And six months after the transplant, he's back to running his cattle again. And he can, in fact, see a snake on the ground or see a barbed wire fence from his horse or tell whether or not a distant shadow is a cow or something else. And so it's made a huge difference for him in his life.
STEIN: Isabella Bewkes (ph) of Santa Rosa, California has been legally blind for more than 40 years. But within weeks of getting the cells, she started to see better. She could make out the cursor on her computer screen, the color of her clothes. Today, she can hike the hills near her house all by herself.
ISABELLA BEWKES: The improvement, I mean from where I was coming, is just - it's very, very significant for me. I think it's fantastic. I just think to be part of groundbreaking research work is amazing.
STEIN: This research is controversial. Embryos are destroyed to get the cells. Some people think that's immoral. For his part, Schwartz says he's just trying to help blind people see better. But he cautions that this work is still at a very early stage. He's only treated a few dozen patients altogether so far and followed them for just 22 months.
SCHWARTZ: I don't want to increase suffering by creating expectations that can't be met.
STEIN: Other researchers agree that these findings need to be considered preliminary, but they say the results so far are really promising. Anthony Atala is at Wake Forest University.
ANTHONY ATALA: It's really a very important paper because it really does show for the very first time that patients can in fact benefit from the therapy that allows you to say OK, now these cells have been used for patients who have blindness. Maybe we can also use these cells for many other conditions as well, including heart disease and lung disease and other medical conditions.
STEIN: Schwartz has continued treating more blind patients using bigger doses of cells and trying it on patients who haven't lost as much vision to see if that works even better. He's also expanded his study to Boston, Miami, Philadelphia and London. Rob Stein, NPR News.
Copyright © 2014 NPR. All
rights reserved. No quotes from the materials contained herein may be
used in any media without attribution to NPR. This transcript is
provided for personal, noncommercial use only, pursuant to our Terms of
Use. Any other use requires NPR's prior permission. Visit our
permissions page for further information.
NPR
transcripts are created on a rush deadline by a contractor for NPR, and
accuracy and availability may vary. This text may not be in its final
form and may be updated or revised in the future. Please be aware that
the authoritative record of NPR's programming is the audio.
No comments:
Post a Comment